Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13664669 | 0.79 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL14936244 | 0.79 | DGAT1 (0.41) | DGAT1 | |
| SCHEMBL2647194 | 0.77 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL30234219 | 0.76 | GAA (0.36) | — | |
| SCHEMBL7839348 | 0.76 | MEN1 (0.40) | — | |
| SCHEMBL27231084 | 0.74 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL14299531 | 0.74 | DGAT1 (0.44) | DGAT1KCNN4 | |
| SCHEMBL28678 | 0.74 | DGAT1 (0.44) | DGAT1KCNN4 | |
| SCHEMBL28677 | 0.74 | DGAT1 (0.44) | DGAT1KCNN4 | |
| SCHEMBL10449706 | 0.73 | ALDH1A1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4380990-A1 | DUAL-CURE RESIN COMPOSITION COMPRISING URETDIONE-CONTAINING COMPOUND AND ITS USE IN 3D PRINTING | BASF SE (DE) | 2024-06-12 | — | — | EP | disclosed |
| CN-117836344-A | Dual cure resin composition comprising uretdione containing compounds and use thereof in 3D printing | 巴斯夫欧洲公司 | 2024-04-05 | — | — | CN | disclosed |
| WO-2024033289-A1 | A PHOTOCURABLE OLIGOMER CONTAINING URETDIONE GROUPS, METHOD OF PREPARING THE OLIGOMER AND DUAL-CURE RESIN COMPOSITION CONTAINING THE OLIGOMER THEREOF | BASF SE (DE) | 2024-02-15 | — | — | WO | disclosed |
| US-11834421-B2 | Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2023-12-05 | — | — | US | disclosed |
| CN-111741948-B | Saturated ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | 日本烟草产业株式会社 | 2023-11-10 | — | — | CN | disclosed |
| EP-3760619-B1 | SATURATED RING-CONDENSED DIHYDROPYRIMIDINONE OR DIHYDROTRIAZINONE COMPOUND, AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2023-10-25 | — | — | EP | disclosed |
| WO-2023012000-A1 | DUAL-CURE RESIN COMPOSITION COMPRISING URETDIONE-CONTAINING COMPOUND AND ITS USE IN 3D PRINTING | BASF SE (DE) | 2023-02-09 | — | — | WO | disclosed |
| CN-111868130-B | Composition, bonding method and assembly | 3M创新有限公司 | 2022-06-24 | — | — | CN | disclosed |
| CN-111788246-B | Composition, bonding method and bonded assembly | 3M创新有限公司 | 2022-06-10 | — | — | CN | disclosed |
| US-20220119355-A1 | SATURATED-RING-FUSED DIHYDROPYRIMIDINONE OR DIHYDROTRIAZINONE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2022-04-21 | — | — | US | disclosed |
| US-4407814-A | ANTIANDROGENS, 3-(HALO- AND/OR TRIFULOROMETHYL-PHENYL)-4,4-DIMETHYL-HYDANTOINS AND IMINO DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 1983-10-04 | — | — | US | disclosed |
| EP-0001813-B1 | IMIDAZOLIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION, INTERMEDIATES FOR USE IN THIS PROCESS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THE USE OF THE ACTIVE COMPOUNDS | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1981-11-04 | — | — | EP | disclosed |
| US-4234736-A | FLUOROPHENYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 1980-11-18 | — | — | US | disclosed |
| EP-0000023-B1 | OMEGA-SUBSTITUTED PENTYL UREAS, THEIR PREPARATION AND THEIR USE AS FUNGICIDES | BAYER AG (DE) | 1980-07-23 | — | — | EP | disclosed |
| US-4188401-A | Combating fungi with 1-(ω-substituted pentyl)-3-(2-cyano-acetyl)-ureas | BAYER AKTIENGESELLSCHAFT (DE) | 1980-02-12 | — | — | US | disclosed |
| EP-0001813-A1 | Imidazolidine derivatives, process for their preparation, intermediates for use in this process, pharmaceutical compositions containing them and the use of the active compounds | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1979-05-16 | — | — | EP | disclosed |
| EP-0000023-A1 | Omega-substituted pentyl ureas, their preparation and their use as fungicides | BAYER AG (DE) | 1978-12-20 | — | — | EP | disclosed |
| US-4079147-A | Fungicidally active derivatives of carbamic acid oxime-esters of isonitrosocyanoacetic acid | BAYER AKTIENGESELLSCHAFT (DT) | 1978-03-14 | — | — | US | disclosed |
| US-4000274-A | PHARMACEUTICAL COMPOSITIONS CONTAINING AN N-ARYL-N'-(PHENYL-OR-PHENOXY-ALKYL)-PIPERAZINE AND METHOD OF USE | BOEHRINGER INGELHEIM GMBH (DT) | 1976-12-28 | — | — | US | disclosed |
| US-3941789-A | CNS DEPRESSANT, ADRENOLYTIC, ANTIPHLOGISTIC, ANALGESIC, ANTIHISTAMINE, ANTICHOLESTEROL | BOEHRINGER INGELHEIM GMBH (DT) | 1976-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834421-B2 | Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | RORC, RORB, RORA | DGAT1 1871/4885KCNN4 1777/4885NPSR1 253/4885 |
| US-20220119355-A1 | SATURATED-RING-FUSED DIHYDROPYRIMIDINONE OR DIHYDROTRIAZINONE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | RORC, RORB, RORA | DGAT1 1871/4885KCNN4 1777/4885NPSR1 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.